Department of Surgery, Faculty of Medicine, Universiti Malaya, 50603, Kuala Lumpur, Malaysia.
BMC Surg. 2022 Apr 21;22(1):146. doi: 10.1186/s12893-022-01594-z.
The effectiveness of hemorrhoidal artery ligation supplementation in reducing the incidence of post laser hemorrhoidoplasty bleeding has not been investigated.
This was a double-blind, randomized controlled trial comparing post-operative bleeding incidence in patients undergoing laser hemorrhoidoplasty (LHP) only versus LHP with hemorrhoidal artery ligation (HAL). Outcome measures included post-operative bleeding and its severity (i.e. verbal rating scale and Clavien-Dindo classification), presence of perianal swelling and pain score (visual analog score) at 1-day, 1-week and 6-weeks post-operatively. Statistical tests were performed and a value of P < 0.05 was considered significant.
Seventy-six patients were randomized. There was no difference in median operating time. The bleeding incidence was highest at 1-week post-operatively (17.1%), and decreased to 1.3% at 6-weeks. There was no significant difference in bleeding incidence between both groups at any of the measured timepoints (P > 0.05). Severity of bleeding and incidence of post-operative perianal swelling were similar in both groups (P > 0.05). There was no difference in median pain scores.
Supplementation of HAL to LHP does not reduce the post-operative bleeding incidence. LHP is sufficient as a stand-alone procedure for treating haemorrhoids.
National Registration Number is NMRR-15-1112-24065 (IIR). The trial start date was 1st January 2015 with the ClinicalTrials.gov identifier and registration number as NCT04667169.
痔动脉结扎术对减少激光痔术后出血的效果尚未得到研究。
这是一项比较单纯激光痔切除术(LHP)与 LHP 联合痔动脉结扎术(HAL)术后出血发生率的双盲、随机对照试验。主要观察指标包括术后出血及其严重程度(即视觉模拟评分和 Clavien-Dindo 分级)、术后 1 天、1 周和 6 周时的肛门周围肿胀和疼痛评分(视觉模拟评分)。进行了统计学检验,P 值<0.05 被认为具有统计学意义。
共 76 例患者被随机分组。两组患者的中位手术时间无差异。术后 1 周出血发生率最高(17.1%),术后 6 周降至 1.3%。在任何测量时间点,两组间出血发生率均无显著差异(P>0.05)。两组间出血严重程度和术后肛门周围肿胀发生率相似(P>0.05)。两组的中位疼痛评分无差异。
HAL 对 LHP 的补充并不能降低术后出血发生率。LHP 作为一种独立的痔治疗方法已足够。
国家注册编号是 NMRR-15-1112-24065(IRR)。试验开始日期为 2015 年 1 月 1 日,ClinicalTrials.gov 标识符和注册号为 NCT04667169。